Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Other 1

Conditions

Endometrial Neoplasms 2Recurrence 1Overweight 1Osteoporosis 1Obesity 1Neoplasms 1Myocardial Ischemia 1Heart Diseases 1Endometrial Hyperplasia 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1Bone Diseases 1

Interventions

Paclitaxel 95Carboplatin 77pembrolizumab 74Cisplatin 29Bevacizumab 27Letrozole 22Radiotherapy 21Doxorubicin 21Megestrol Acetate 20lenvatinib 19olaparib 18Taxes 17Docetaxel 17Nivolumab 16Specimen Handling 15Metformin 15dostarlimab 14Magnetic Resonance Spectroscopy 14Gemcitabine 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11Biopsy 11temsirolimus 10abemaciclib 10atezolizumab 9Radiation 9Early Intervention, Educational 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Endometrial Neoplasms × Estrogen Replacement Therapy × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

NCT03077698 2022-06-07

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Xenetic Biosciences, Inc.

Phase 2 Terminated
25 enrolled 14 charts
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡